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Masses in spleens or livers of dogs are rela-
tively common findings for the veterinarian.
They are often noted during the routine physi-
cal exam or during ultrasound imaging of the
abdomen. These lesions may be a result of
trauma, hyperplasia, and benign or malignant
tumors. Benign lesions in the liver are more
common than malignant ones, though clini-
cians cannot automatically assume that a mass
is benign. To determine the character of a
lesion, ultrasound and biopsies are used as
diagnostic tools.
Ultrasound is
an excellent
modality for
determining the
presence of a
mass but often
the ultrasonog-
rapher cannot
say whether it is
truly benign or
malignant. That
is determined
definitively only
by biopsy. In
human medi-
cine, for a num-
ber of years,
MRI imaging
has been used to
characterize
lesions in the
liver and spleen.
MRI images have
advantages over
ultrasound images in providing a much more
defined, soft tissue imaging modality. MRI is
considered the “Gold Standard” of imaging for
the liver and spleen in people. MRI in people
can not only determine whether a lesion is
benign or malignant, but can further define
whether it is a primary or metastatic (cancer
spread) lesion. To determine whether canine
benign and malignant tumors in the spleen
and liver can be diagnosed through MRI, clini-
cians at VHUP and at HUP, (the hospital for
humans a few blocks away), designed a study
for MRI screening of dogs with focal splenic
and liver lesions.
Dogs, unlike humans, have to be anes-
thetized for an MRI as they are required to be
perfectly still. Cases were selected from patients
presented at VHUP’s clinics. The study exam-
ined 20 dogs that had been scheduled for a
splenectomy and/or liver biopsy.
The dogs were taken to a research MRI at
HUP. Technicians and clinicians from VHUP
accompanied the animals to handle anesthesia
and contrast medium infusion. The MRI
images were read by two radiologists (Drs. E.S.
Pretorius and E. Siegelman) from HUP who
used guidelines established for liver and splenic
tumors in humans.
The animals then underwent a liver biopsy
or splenectomy and the removed tissues were
then examined by the veterinary school’s
pathologists. The MRI imaging characteristics
were correlated with the pathologic findings to
determine whether the expected MRI imaging
characteristics of benign and maligant canine
spleenic and liver lesions were the same as such
lesions in humans.
Using the MRI imaging characteristics for
human benign and malignant liver and spleen
lesions, radiologists at HUP identified 16 out of
17 benign lesions and 15 out of 15 malignant
lesions. The overall accuracy was 31/32 lesions
thus far. These findings were confirmed by the
histopathology exam of biopsied or removed
tissues. The animals were also examined by
ultrasound, however, in the majority of cases,
no specific diagnosis was given, so comparisons
between MRI and ultrasound were not
possible.
In two cases the MRI found pulmonary
metastasis not seen on radiographs. MRI also
showed the exact location of the tumor, mak-
ing it easier for surgeons if removal was
required in several cases.
“It appears that MRI imaging maybe a use-
ful screening method for canine patients with
focal splenic or liver lesions,” says Dr. Craig
Clifford, resident in oncology and primary
investigator.
“We are
enlarging the
study to look
at a bigger
group. If the
results hold
true, then it is
possible that
some biopsies
and surgeries
of benign
lesions can be
prevented. The
MRI modality
also shows a
more exact
location of a
mass, making
it easier for the
surgeon, in
several cases,
MRI provided
the surgeon
with valuable
information. One additional benefit of MRI
and its superior soft tissue imaging is that we
can use it to follow a tumor while it is treated
with chemotherapy; the MRI allows us to see
whether the tumor is shrinking. This is partic-
ularly important when new drug regimens
which are designed to kill the blood vessels
supplying the tumor are tried, for example, for
hemangiosarcomas” (blood vessel tumor).
The clinicians participating in the initial
pilot study are Drs. Clifford, Chick Weisse,
V’98, and Karin Sorenmo of VHUP, and E.S.
Pretorius, E. Siegelman and J.A. Solomon of
HUP. This study was presented by Dr. Clifford
at the 22nd Annual Veterinary Cancer Society
Conference in New York this past September
and received the Clinical Research Award.
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T2 image T1 Late Post-Gad
A mass diagnosed as a cancer based upon abnormal appearance on the T2 image and called a hepatocellular carcinoma due to sim-
ilarities to the rest of the liver on the T1 image. It was read as “low-grade” because it did not contrast enhance. This was proven
after surgical resection of the tumor.
